Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | SETD2 | Q9BYW2 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640876 | 0.93 | CHRNA7 (0.39) | CHRNA7DRD2SETD2ACKR3DPP4 | |
| SCHEMBL13640795 | 0.91 | CHRNA7 (0.39) | CHRNA7DRD2SETD2HRH3ACKR3 | |
| SCHEMBL13640995 | 0.90 | CHRNA7 (0.41) | CHRNA7DRD2SETD2HRH3ACKR3 | |
| SCHEMBL13640994 | 0.89 | CHRNA7 (0.38) | CHRNA7DRD2SETD2ACKR3DPP4 | |
| SCHEMBL13640837 | 0.89 | CHRNA7 (0.39) | CHRNA7DRD2SETD2ACKR3DPP4 | |
| SCHEMBL13640938 | 0.89 | CHRNA7 (0.37) | CHRNA7DRD2SETD2HRH3ACKR3 | |
| SCHEMBL13641035 | 0.89 | CHRNA7 (0.37) | CHRNA7DRD2SETD2HRH3ACKR3 | |
| SCHEMBL13640793 | 0.88 | CHRNA7 (0.37) | CHRNA7DRD2SETD2HRH3ACKR3 | |
| SCHEMBL13640844 | 0.88 | CHRNA7 (0.38) | CHRNA7DRD2SETD2ACKR3AKR1B1 | |
| SCHEMBL13640947 | 0.86 | CHRNA7 (0.41) | CHRNA7DRD2SETD2ACKR3CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | CHRNA7 23/4885DRD2 491/4885SETD2 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.